Barclays raised the firm’s price target on Ionis Pharmaceuticals (IONS) to $95 from $80 and keeps an Overweight rating on the shares. The company reported a second consecutive beat quarter for Tryngolza and raised 2025 revenue guidance, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IONS:
- Ionis Pharmaceuticals: Strong Q3 Performance and Promising Pipeline Drive Buy Rating
- Ionis Pharmaceuticals Reports Strong Q3 2025 Growth
- Ionis Pharmaceuticals Shines in Q3 2025 Earnings Call
- Ionis Pharmaceuticals: Strong Growth Potential and Strategic Advancements Drive Buy Rating
- Ionis Pharmaceuticals: A Compelling Buy with Strong Performance and Promising Growth Catalysts